Actinogen Medical Revenue
Biotechnology Research • 
Sydney, New South Wales, Australia • 11-20 Employees
Actinogen Medical revenue & valuation
| Annual revenue | $1,454,435 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $4,700,000 |
| Total funding | No funding |
Key Contacts at Actinogen Medical
George Morstyn Ftse
Director
Lee Bergman
Associate Director Regulatory And Medical Writing
Company overview
| Headquarters | Suite 901, Level 9, 109 Pitt Street, Sydney, NSW 2000, AU |
| Phone number | +61289647401 |
| Website | |
| SIC | 283 |
| Keywords | Biotechnology, Clinical Development, Pharmaceuticals, Clinical Research |
| Founded | 2014 |
| Employees | 11-20 |
| Socials |
Actinogen Medical Email Formats
Actinogen Medical uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@actinogen.com.au), used 85.7% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@actinogen.com.au | 85.7% |
{first name}.{last name} | john.doe@actinogen.com.au | 14.3% |
About Actinogen Medical
Actinogen Medical (ASX:ACW) is an ASX-listed biotechnology company developing a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. There is a strong association between persistent stress and the production of excess cortisol that leads to changes in the brain affecting memory, cognitive function, behaviour and neuropsychological symptoms. Actinogen’s lead compound, Xanamem, has been specifically designed to reduce production of intracellular cortisol - the stress hormone - through the inhibition of the 11β-HSD1 enzyme in the brain. The 11β-HSD1 enzyme is highly concentrated in the areas of the brain associated with cognitive impairment in early Alzheimer’s Disease (AD) and Depression, and other neurological and psychiatric diseases. Because of its ability to reach these areas of the brain and inhibit this enzyme, Xanamem is very different from other treatments for cognitive impairment. Actinogen has studied 11β-HSD1 inhibition by Xanamem in more than 300 volunteers and patients, so far finding a statistically significant improvement in working memory and attention, compared with placebo, in healthy, older volunteers in two consecutive trials and clinically significant improvements in patients with biomarker-positive mild AD. Previously, high levels of target engagement in the brain with doses as low as 5 mg daily have been demonstrated in a human PET imaging study. The Company is rapidly moving forward into its upcoming double-blind, randomized, placebo-controlled Phase 2 trials in cognitive impairment in Alzheimer’s Disease and Depression to further confirm and characterize Xanamem’s therapeutic potential. The XanaMIA Phase 2b AD trial comprises 330 patients with mild Alzheimer’s Disease and the XanaCIDD Phase 2a trial will total 160 patients with depression.
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
Actinogen Medical has 8 employees across 6 departments.
Departments
Number of employees
Actinogen Medical Tech Stack
Discover the technologies and tools that power Actinogen Medical's digital infrastructure, from frameworks to analytics platforms.
Video players
Security
JavaScript frameworks
JavaScript libraries
JavaScript libraries
JavaScript libraries
JavaScript libraries
Page builders
JavaScript graphics
JavaScript libraries
JavaScript libraries
Web servers
Canada
South Africa
France
Saudi Arabia
United States
Frequently asked questions
4.8
40,000 users
